S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic

Data Knights Acquisition (DKDCA) Competitors

$0.80
-0.18 (-18.40%)
(As of 03/1/2024 ET)

DKDCA vs. ISPC, AIKI, BIOL, PHAS, VRPX, NBSE, ONCO, ARDS, AIMD, and PTPI

Should you be buying Data Knights Acquisition stock or one of its competitors? The main competitors of Data Knights Acquisition include iSpecimen (ISPC), AIkido Pharma (AIKI), BIOLASE (BIOL), PhaseBio Pharmaceuticals (PHAS), Virpax Pharmaceuticals (VRPX), NeuBase Therapeutics (NBSE), Onconetix (ONCO), Aridis Pharmaceuticals (ARDS), Ainos (AIMD), and Petros Pharmaceuticals (PTPI). These companies are all part of the "medical" sector.

Data Knights Acquisition vs.

iSpecimen (NASDAQ:ISPC) and Data Knights Acquisition (NASDAQ:DKDCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

4.6% of iSpecimen shares are owned by institutional investors. Comparatively, 35.3% of Data Knights Acquisition shares are owned by institutional investors. 32.7% of iSpecimen shares are owned by company insiders. Comparatively, 45.7% of Data Knights Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, iSpecimen had 2 more articles in the media than Data Knights Acquisition. MarketBeat recorded 2 mentions for iSpecimen and 0 mentions for Data Knights Acquisition. Data Knights Acquisition's average media sentiment score of 1.44 beat iSpecimen's score of 0.00 indicating that iSpecimen is being referred to more favorably in the media.

Company Overall Sentiment
iSpecimen Positive
Data Knights Acquisition Neutral

Data Knights Acquisition has lower revenue, but higher earnings than iSpecimen. Data Knights Acquisition is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iSpecimen$10.40M0.40-$10.25M-$1.13-0.41
Data Knights AcquisitionN/AN/A$340K-$0.19-4.20

iSpecimen received 3 more outperform votes than Data Knights Acquisition when rated by MarketBeat users.

CompanyUnderperformOutperform
iSpecimenOutperform Votes
3
75.00%
Underperform Votes
1
25.00%
Data Knights AcquisitionN/AN/A

Data Knights Acquisition has a net margin of 0.00% compared to Data Knights Acquisition's net margin of -98.76%. iSpecimen's return on equity of 0.00% beat Data Knights Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
iSpecimen-98.76% -61.92% -50.67%
Data Knights Acquisition N/A N/A -5.55%

iSpecimen has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, Data Knights Acquisition has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iSpecimen
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Data Knights Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Data Knights Acquisition beats iSpecimen on 7 of the 13 factors compared between the two stocks.


Get Data Knights Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for DKDCA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DKDCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DKDCA vs. The Competition

MetricData Knights AcquisitionCommercial physical research IndustryMedical SectorNASDAQ Exchange
Market Cap$4.13M$5.25B$5.11B$7.64B
Dividend YieldN/A0.95%2.82%3.87%
P/E Ratio-4.2012.22192.1515.82
Price / SalesN/A71.063,058.6877.06
Price / Cash111.4228.22100.8155.48
Price / Book-0.443.894.534.53
Net Income$340,000.00$128.37M$115.01M$211.55M
7 Day Performance15.16%5.16%5.72%3.36%
1 Month Performance-33.46%9.95%12.82%6.70%
1 Year Performance-92.53%-5.48%12.95%7.44%

Data Knights Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ISPC
iSpecimen
0 of 5 stars
$0.44
-4.4%
N/A-69.6%$3.99M$10.40M-0.3975Short Interest ↓
Gap Down
AIKI
AIkido Pharma
0 of 5 stars
$2.14
+3.9%
N/A-50.5%$11.71M$10,000.00-0.554Gap Down
BIOL
BIOLASE
1.9964 of 5 stars
$0.15
flat
$77.00
+51,751.9%
-99.7%$3.47M$48.46M0.00188Analyst Report
Short Interest ↑
PHAS
PhaseBio Pharmaceuticals
0 of 5 stars
N/AN/AN/A$3.50M$818,000.00-0.0360
VRPX
Virpax Pharmaceuticals
0 of 5 stars
$0.29
-14.7%
N/A-63.7%$3.40MN/A-0.257Stock Split
News Coverage
Gap Down
NBSE
NeuBase Therapeutics
2.2984 of 5 stars
$0.91
-1.1%
N/A-78.0%$3.40MN/A-0.1237Upcoming Earnings
Short Interest ↓
News Coverage
Gap Up
ONCO
Onconetix
0 of 5 stars
$0.18
+5.9%
N/AN/A$3.36MN/A-0.1712Short Interest ↑
ARDS
Aridis Pharmaceuticals
0.5016 of 5 stars
$0.08
flat
$2.00
+2,566.7%
-85.8%$3.60M$3.09M-0.4737
AIMD
Ainos
0 of 5 stars
$0.81
-1.2%
N/AN/A$3.30M$1.14M-0.3243Positive News
Gap Up
PTPI
Petros Pharmaceuticals
2.7344 of 5 stars
$1.66
+5.1%
$4.00
+141.0%
-8.2%$3.65M$5.99M0.0024Gap Up

Related Companies and Tools

This page (NASDAQ:DKDCA) was last updated on 3/3/2024 by MarketBeat.com Staff